Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04799002

Topotecan and Melphalan for Retinoblastoma

The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Retinoblastoma Chemotherapy Effect Eye Diseases Eye Diseases, Hereditary Eye Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors Retinal Diseases Retinal Neoplasms

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

About this study

To evaluate the effectiveness and complications of topotecan and melphalan for intraocular injection in retinoblastoma patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • diagnosed as retinoblastoma
  • receiving eyeball-sparing treatment

Exclusion criteria

  • disease progression during follow-up

Treatment and study plan

Topotecan

Drug

Topotecan intraocular injection for chemotherapy in retinoblastoma

Other names: Topotecan intraocular injection

melphalan

Drug

Melphalan intraocular injection for chemotherapy in retinoblastoma

Other names: Melphalan intraocular injection

Primary outcomes

  1. Eyeball-sparing rate

    Time frame: 5 years after chemotherapy

    Eyeball-sparing rate during chemotherapy in retinoblastoma patients

Secondary outcomes

  1. Side effects

    Time frame: 5 years after chemotherapy

    Side effects during and after chemotherapy in retinoblastoma patients

Study contacts

Contact information is provided by the study sponsor or research team.

Huasheng Yang

CONTACT

[email protected]

+00862087331539

Huijing Ye

CONTACT

[email protected]

+00862087331539

Sponsors and collaborators

Lead sponsor

Sun Yat-sen University

Other

Registry information

Official study title

Choice of Topotecan or Melphalan in Retinoblastoma Patients

Important dates

Study start
2021
Primary completion
2024
Study completion
2027
First posted
Mar 16, 2021
Registry last updated
Mar 16, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.